Read the #TenTweetNephJC summary of the ADMIRAL study, examining how dd-cfDNA monitoring may help us manage our patients with renal transplants.
This week, we will discuss the ongoing saga of blood pressure targets in patients with hypertension. This time its ESPRIT (Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing Risk of Vascular Events) making a case for case for intensive BP control in most hypertensive individuals, including those with a history of diabetes and stroke.
Read the #TenTweetNephJC summary of the ADMIRAL study, examining how dd-cfDNA monitoring may help us manage our patients with renal transplants.
1. Does transplant medicine have a new blood test that is better than creatinine?
— Nephrology Jrnl Club (@NephJC) July 1, 2022
Aye aye ADMIRAL 🫡
Join us as we recap last week's #NephJC chat on this edition of #TenTweetNephJC brought to you by @jamiekwillows and @michaelturk6 pic.twitter.com/gAS70VKG8i